Investment
Features
FeesSafety
Academy
More
Pluang+

Pump.fun adds tokens for 8 private companies, excluding U.S. persons, on Solana blockchain.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Pump.fun adds tokens for 8 private companies, excluding U.S. persons, on Solana blockchain.

Pump.fun integrated PreStocks tokens linked to eight private companies—OpenAI, Anthropic, Anduril, Neuralink, Figure AI, Kalshi, Polymarket, and Oura—into its trading platform on October 19. These tokens, issued on the Solana blockchain, allow traders to exchange them and creators to pair them with new coins, but they do not confer equity ownership, voting rights, or dividends. The tokens are not available to U.S. persons and are not endorsed by the companies they reference. This addition expands Pump.fun's asset offerings, which already include tokenized stocks and other assets since September 9.

Pump.fun's addition of tokens linked to eight private companies provides context for digital asset interest. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 20, 2026 07:21 WIB: among 50 major cryptocurrencies, 32 rose and 17 fell today. Notable movers include EGLD (MultiversX) with a 1-day change of +2.68% and typical hold time on Pluang of 86 days, ZIL (Zilliqa) down -2.43% with a hold time of 133 days, and COMP (Compound) up +2.32% with a hold time of 98 days and a strong buy order activity of 99%.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

XRP market value drops $61B in a year as Evernorth launches XRP treasury company on Nasdaq

XRP's circulating market value fell by $61.14 billion, or 42.64%, from $143.38 billion on Oct. 19, 2025, to $82.24 billion a year later, driven by a price drop from $2.39 to $1.30 despite a slight increase in circulating supply. Meanwhile, Evernorth ...

Market News
Neutral
4 hours ago
Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly's revenue grows 20% with strong product expansion, yet valuation undervalues its potential.

Remitly reported a 20% year-over-year revenue increase to $495 million, supported by 10.2 million active customers and a 197% rise in Free Cash Flow. The company is expanding its product offerings with the Remitly Card and Pay Later services, which, ...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App